| 9MW2821 / Mabwell (Shanghai) Biosci |
9MW2821-2023-CP301, CTR20234024: A randomized, open-label, controlled, multicenter phase III clinical study of 9MW2821 versus investigator-selected chemotherapy for the treatment of unresectable locally advanced or metastatic urothelial carcinoma previously treated with platinum-containi |
|
|
| Not yet recruiting | 3 | 420 | China | 9MW2821 - Mabwell (Shanghai) Biosci, docetaxel - Generic mfg., paclitaxel - Generic mfg. | Jiangsu Maweikang New Drug R&D Co., Ltd | Urothelial carcinoma | | | | |
NCT06196736: A Study to Evaluate 9MW2821 Versus Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer |
|
|
| Not yet recruiting | 3 | 420 | RoW | 9MW2821, Chemotherapy | Mabwell (Shanghai) Bioscience Co., Ltd. | Advanced Urothelial Carcinoma | 12/26 | 12/28 | | |
9MW2821-2023-CP104, CTR20232677: An open-label, single-arm, multicenter Phase Ib/II clinical study evaluating the safety and efficacy of 9MW2821 in combination with toripalimab injection in patients with locally advanced or metastatic urothelial carcinoma |
|
|
| Ongoing | 1b/2 | 100 | China | 9MW2821 - Mabwell (Shanghai) Biosci, Loqtorzi (toripalimab) - Shanghai Junshi Biosci, Coherus Biosci | Jiangsu Maweikang New Drug R&D Co., Ltd | Urothelial carcinoma | | | | |
| Recruiting | 1/2 | 208 | RoW | 9MW2821 | Mabwell (Shanghai) Bioscience Co., Ltd. | Solid Tumors | 12/25 | 12/25 | | |
NCT06079112: 9MW2821 Combined With Toripalimab Injection in Subjects With Local Advanced or Metastatic Urothelial Cancer |
|
|
| Not yet recruiting | 1/2 | 100 | RoW | 9MW2821, 9MW2821 injection, Toripalimab, Toripalimab injection | Mabwell (Shanghai) Bioscience Co., Ltd. | Advanced Urothelial Carcinoma | 12/26 | 12/27 | | |
NCT05773937: A Clinical Study of 9MW2821 in Advanced Malignant Solid Tumors |
|
|
| Recruiting | 1 | 40 | RoW | 9MW2821 | Mabwell (Shanghai) Bioscience Co., Ltd. | Advanced Malignant Solid Tumors | 12/24 | 12/24 | | |